LivaNova (NASDAQ:LIVN) Upgraded by Wall Street Zen to "Strong-Buy" Rating

Key Points

• LivaNova's stock has been upgraded to a "strong-buy" rating by Wall Street Zen, reflecting increasing confidence in the company's prospects.
• Analysts have set a consensus price target of $59.29, with multiple firms indicating an optimistic outlook on the stock.
• The company reported a positive earnings surprise with $1.05 EPS, exceeding the consensus estimate by $0.21, and achieved a revenue of $352.50 million for the quarter.

LivaNova (NASDAQ:LIVN - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued to clients and investors on Saturday.

A number of other research firms have also recently weighed in on LIVN. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target on the stock in a research note on Tuesday, May 20th. Robert W. Baird lifted their price objective on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Barclays lowered their price objective on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 8th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a research note on Tuesday, May 13th. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $59.29.

LivaNova Trading Up 1.5%

Shares of LIVN traded up $0.72 during trading on Friday, reaching $49.56. 850,997 shares of the company traded hands, compared to its average volume of 710,863. LivaNova has a twelve month low of $32.48 and a twelve month high of $57.35. The stock has a market cap of $2.71 billion, a PE ratio of -12.74 and a beta of 0.92. The stock has a 50-day simple moving average of $45.06 and a 200-day simple moving average of $42.74. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.21. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The business had revenue of $352.50 million during the quarter, compared to the consensus estimate of $332.20 million. During the same quarter in the previous year, the firm earned $0.93 EPS. The company's revenue was up 10.6% compared to the same quarter last year. On average, analysts anticipate that LivaNova will post 2.85 earnings per share for the current year.

Hedge Funds Weigh In On LivaNova

A number of hedge funds have recently added to or reduced their stakes in LIVN. Primecap Management Co. CA lifted its stake in LivaNova by 0.7% in the second quarter. Primecap Management Co. CA now owns 4,641,352 shares of the company's stock valued at $208,954,000 after buying an additional 32,942 shares during the last quarter. LSV Asset Management raised its stake in shares of LivaNova by 22.7% during the second quarter. LSV Asset Management now owns 538,010 shares of the company's stock valued at $24,221,000 after purchasing an additional 99,512 shares in the last quarter. Ontario Teachers Pension Plan Board bought a new stake in shares of LivaNova during the second quarter valued at about $3,029,000. Creative Planning bought a new stake in shares of LivaNova during the second quarter valued at about $1,123,000. Finally, SG Americas Securities LLC raised its position in LivaNova by 4,082.6% in the second quarter. SG Americas Securities LLC now owns 202,144 shares of the company's stock worth $9,101,000 after acquiring an additional 197,311 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.